SCHEMBL648390

SCHEMBL648390

CCCCn1c(CN(Cc2ccc3c(c2)OCO3)CC2CCCCC2)nnc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
TSHR P16473 7/20 0.41
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
F2R P25116 4/20 0.39
ALDH1A1 P00352 6/20 0.39
NPSR1 Q6W5P4 5/20 0.39
HSD17B10 Q99714 4/20 0.39
HTT P42858 3/20 0.39
USP2 O75604 3/20 0.39
KDM4E B2RXH2 3/20 0.38
ALOX15 P16050 2/20 0.38
CASP1 P29466 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSP90AA1 P07900 2/20 0.38
HSP90AB1 P08238 2/20 0.38
CYP1A2 P05177 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648195 0.90 C5AR1 (0.63) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL649845 0.87 C5AR1 (0.60) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5135146 0.86 C5AR1 (0.53) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5136016 0.86 C5AR1 (0.53) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL649149 0.85 C5AR1 (0.64) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5138040 0.85 C5AR1 (0.54) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL649999 0.85 C5AR1 (0.56) C5AR1SMN1; SMN2TDP1LMNAL3MBTL1
SCHEMBL5136927 0.83 C5AR1 (0.54) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5136221 0.81 C5AR1 (0.56) C5AR1SMN1; SMN2TDP1TSHRLMNA
SCHEMBL5135945 0.80 C5AR1 (0.57) C5AR1SMN1; SMN2TDP1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed